Altimmune, Inc (ALT)

Etorro trading 970x250
Altimmune, Inc (ALT) Logo

About Altimmune, Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland. Address: 910 Clopper Road, Gaithersburg, MD, United States, 20878

Altimmune, Inc News and around…

Latest news about Altimmune, Inc (ALT) common stock and company :

Altimmune to Present at Upcoming Investor and Scientific Conferences
22 Nov, 2021 Yahoo! Finance

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences: Piper Sandler 33rd Annual Virtual Healthcare ConferenceNovember 29-December 2, 2021Webcast available now 5th Annual NASH Summit 2021November 30, 20219:00 am Eastern Time 4th Annual Evercore ISI HealthCONx ConferenceDecember 2, 202110:55 am Eastern Tim

ALTIMMUNE INC (ALT) Q3 2021 Earnings Call Transcript
11 Nov, 2021 FinancialContent

ALT earnings call for the period ending September 30, 2021.

Altimmune to Present at Upcoming Investor Conferences
10 Nov, 2021 Yahoo! Finance

GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following investor conferences in November 2021: Stifel’s 2021 Virtual Healthcare ConferenceMonday, November 15, 202110:40 am Eastern Time Jefferies London Healthcare ConferenceThursday, November 18, 20218:00 am GMT The sessions will be webcast and can be accessed by visiti

Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
09 Nov, 2021 Yahoo! Finance

Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment Approximately $200 Million in cash and short-term investments to advance pipeline GAITHERSBURG, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and nine-months ending September 30, 2021 and

Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
03 Nov, 2021 Yahoo! Finance

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021. Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update. Conference Call Information: Date:Wednesday, November 10Time:8:30 am Eastern TimeDomestic

Implied IBB Analyst Target Price: $217
02 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Biotechnology ETF (IBB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $217.20 per unit.

Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
01 Nov, 2021 Yahoo! Finance

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oversold Conditions For Altimmune (ALT)
29 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
16 Oct, 2021 Yahoo! Finance

Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

Stock Upgrades: Altimmune Shows Rising Relative Strength
12 Oct, 2021 FinancialContent

Altimmune shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
06 Oct, 2021 Yahoo! Finance

GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences: H.C. Wainwright 5th Annual NASH Investor ConferenceTuesday, October 12, 20213:30 pm Eastern Time H.C. Wainwright Hepatitis B Virus (HBV) Virtual ConferenceWednesday, October 13, 20214:30 pm Eastern Time The sessions will be webcast and

Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease
04 Oct, 2021 Yahoo! Finance

First patient has been enrolled in 12-week non-alcoholic fatty liver disease (NAFLD) studyDr. Stephen Harrison will be serving as Principal Investigator for the studyTopline data readout expected in the first half of 2022 GAITHERSBURG, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in a Phase 1b clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in subjec

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Altimmune, Inc. (ALT) Investigation
01 Oct, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT).

Look Under The Hood: LABU Has 71% Upside
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $94.28 per unit.

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

52 Biggest Movers From Yesterday
30 Sep, 2021 FinancialContent

Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) ...

Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
29 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's Intraday Session
29 Sep, 2021 FinancialContent

Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current ...

33 Stocks Moving In Wednesday's Mid-Day Session
29 Sep, 2021 FinancialContent

Gainers Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18. NuCana plc (NASDAQ: NCNA) jumped 31.4% to $3.1150. The FDA ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
29 Sep, 2021 FinancialContent

Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The ...

Noteworthy Tuesday Option Activity: ROKU, ALT, CCXI
28 Sep, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Roku Inc (ROKU), where a total of 79,572 contracts have traded so far, representing approximately 8.0 million underlying shares. That amounts to about 208.7% of ROKU's average daily trading volume over the past month of 3.8 million shares..

H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
28 Sep, 2021 FinancialContent

H.C. Wainwright said thatAltimmune Inc(NASDAQ: ALT) reported "positive" Phase 1 trial pemvidutide data, ...

ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34
28 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock. The post ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Dow Set to Snap Win Streak as Tech Sector Weighs
28 Sep, 2021 FinancialContent

The Dow Jones Industrial Average looks ready to snap its four-day win streak, as the tech sector's recent rout catches up with the index, which was last seen down 419 points.

Why Altimmune Stock Is Under Pressure Today
28 Sep, 2021 FinancialContent

Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.

See Why Altimmune Stock Plunged After Obesity Trial Data
28 Sep, 2021 FinancialContent

Altimmune Inc(NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational ...

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
28 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
28 Sep, 2021 FinancialContent

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market ...

Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
28 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's After-Market Session
27 Sep, 2021 FinancialContent

Gainers Paratek Pharmaceuticals (NASDAQ:PRTK) shares moved upwards by 9.7% to $5.65 during Monday's after-market session. Today's ...

Altimmune, Inc (ALT) is a NASDAQ Common Stock listed in , ,

970x250